Pacira BioSciences, Inc.
PCRX
$22.69
-$0.57-2.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 196.87M | 179.52M | 181.10M | 168.92M | 187.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 196.87M | 179.52M | 181.10M | 168.92M | 187.25M |
| Cost of Revenue | 83.25M | 60.24M | 43.27M | 36.55M | 63.78M |
| Gross Profit | 113.62M | 119.27M | 137.83M | 132.38M | 123.47M |
| SG&A Expenses | 101.61M | 91.80M | 88.58M | 86.78M | 79.61M |
| Depreciation & Amortization | 14.32M | 14.32M | 14.32M | 14.32M | 14.32M |
| Other Operating Expenses | -- | -- | -- | 351.00K | -- |
| Total Operating Expenses | 199.18M | 166.36M | 171.97M | 161.10M | 157.72M |
| Operating Income | -2.31M | 13.15M | 9.13M | 7.83M | 29.53M |
| Income Before Tax | 571.00K | 9.52M | -1.93M | 8.71M | 25.53M |
| Income Tax Expenses | -1.07M | 4.09M | 2.92M | 3.89M | 9.49M |
| Earnings from Continuing Operations | 1.64M | 5.43M | -4.85M | 4.81M | 16.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.64M | 5.43M | -4.85M | 4.81M | 16.04M |
| EBIT | -2.31M | 13.15M | 9.13M | 7.83M | 29.53M |
| EBITDA | 24.53M | 28.84M | 36.46M | 28.99M | 50.78M |
| EPS Basic | 0.04 | 0.12 | -0.11 | 0.10 | 0.35 |
| Normalized Basic EPS | -0.06 | 0.25 | -0.02 | 0.14 | 0.41 |
| EPS Diluted | 0.04 | 0.12 | -0.11 | 0.10 | 0.33 |
| Normalized Diluted EPS | -0.06 | 0.24 | -0.02 | 0.14 | 0.39 |
| Average Basic Shares Outstanding | 42.49M | 44.04M | 45.46M | 46.28M | 46.17M |
| Average Diluted Shares Outstanding | 42.98M | 44.46M | 45.46M | 46.53M | 49.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |